

QUT Digital Repository:
<http://eprints.qut.edu.au/>



This is the author version published as:

Woodruff, Maria A. and Narayan Rath, Subha and Susanto, Evelyn and Haupt, Larisa M. and Hutmacher, Dietmar W. and Nurcombe, Victor and Cool, Simon M. (2007) *Sustained release and osteogenic potential of heparan sulfate-doped fibrin glue scaffolds within a rat cranial model*. Journal of Molecular Histology, 38(5). pp. 425-433.

Copyright 2007 Springer Netherlands

**Sustained Release and Osteogenic Potential of Heparan Sulfate-doped Fibrin Glue
Scaffolds within a Rat Cranial Model**

Maria Ann Woodruff^{3*}, Subha Narayan Rath^{3*}, Evelyn Susanto³, Larisa M Haupt¹

Dietmar W Hutmacher^{2,3}, Victor Nurcombe^{1,2}, Simon M Cool^{1,2}

*¹Stem Cells and Tissue Repair Group, Institute of Molecular and Cell Biology, Proteos,
61 Biopolis Drive, Singapore 138673; ²Department of Orthopaedic Surgery, Yong Loo
Lin School of Medicine, National University of Singapore, 119074. ³Division of
Bioengineering, Faculty of Engineering, National University of Singapore, Singapore
119260*

* Authors contributed equally

Glycosaminoglycans, Bone regeneration, Biomaterials, CT scanning

Summary

This paper explores the potential therapeutic role of the naturally occurring sugar heparan sulfate for the augmentation of bone repair. Scaffolds comprising fibrin glue loaded with 5 μg of embryonically-derived heparan sulfate were assessed, firstly as a release-reservoir, and secondly as a scaffold to stimulate bone regeneration in a critical size rat cranial defect. We show heparan sulfate-loaded scaffolds have a uniform distribution of heparan sulfate, which was readily released with a typical burst phase, quickly followed by a prolonged delivery lasting several days. Importantly, the released heparan sulfate contributed to improved wound healing over a 3 month period as determined by μCT scanning, histology, histomorphometry and PCR for osteogenic markers. In all cases, only minimal healing was observed after 1 and 3 months in the absence of heparan sulfate. In contrast, marked healing was observed by 3 months following heparan sulfate treatment, with nearly full closure of the defect site. PCR analysis showed significant increases in the gene expression of the osteogenic markers Runx2, alkaline phosphatase and osteopontin in the heparin sulfate group compared with controls. These results further emphasize the important role heparan sulfate plays in augmenting wound healing, and its successful delivery in a hydrogel provides a novel alternative to autologous bone graft and growth factor-based therapies.

Introduction

The drive to develop bone regenerative therapies to circumvent delayed and non-union of bone fractures is an important therapeutic issue, especially considering the millions of fractures which occur annually, at least 10% of which are unable to heal by themselves. Several growth factors play key roles in the process of bone repair, and studies aimed at elucidating the factors affecting stem cell fate have recently demonstrated that the extracellular glycosaminoglycan sugar heparan sulfate (HS) plays a key role in the proliferation and differentiation of human bone marrow-derived mesenchymal stem cells (Cool & Nurcombe 2005). Osteogenic lineage fate decisions in general are known to be strongly influenced by several heparan-binding growth factors and it is widely accepted that fibroblast growth factors (FGFs) and their receptors (FGFRs) are essential to osteoblast differentiation and proliferation (Fakhry *et al.* 2005, Ornitz *et al.* 2001, Zhang *et al.* 2002). Much evidence has accumulated to show that FGF signaling, together with a large number of other growth and adhesive factors, is in fact controlled by HS (Jackson *et al.* 2006).

Heparan sulfate is member of the glycosaminoglycan family of macromolecules. These are linear polysaccharides consisting of a repeating glucosamine/glucuronic acid disaccharide unit backbone attached to a protein core. HS has highly but variably sulfated sequences contained within its chains, organized into clusters that facilitate protein binding. These sulfated structural domain motifs are primarily responsible for the regulatory properties of HS (Guido *et al.* 1998). HS polysaccharides display versatilities

in conformation and orientation of functional groups which enable them to employ different modes of binding with protein complexes. These selective interactions with certain proteins results in regulation of protein activities (Cool & Nurcombe 2005). HS thus acts as a co-receptor, binding to heparin-binding growth factors such as FGF and BMP2, both protecting them from proteolytic degradation and promoting binding to their high affinity receptors (Turnbull *et al* 2001). HS has a low affinity yet high capacity for its ligands, drawing them onto the cell surface with their high-affinity cognate receptors, which then transduce the appropriate signal into the cells (Lyon *et al.* 1998). Moreover, HS binding is thought to be important in providing a matrix-bound pericellular reservoir of growth factors, promoting their long-term availability to cells (Saksela *et al.* 1989). The interaction of BMPs with their threonine-serine kinase BMP receptors is also thought to be mediated by HS (Irie *et al.* 2003, Takada *et al.* 2003, Coombe *et al.* 2005). And furthermore HS is thought to prevent diffusion of BMP2 *in vivo*, away from the regions where is it likely to be required (Depprich *et al.* 2005).

Due to its ability to bind and potentiate bioactive molecules, there is growing evidence that the ECM-derived HS may prove to be a valuable adjunct for a variety of tissue engineering and wound-healing strategies that currently use growth factor treatments (Coombe *et al.* 2005). HS and its mimetics have been shown to improve bone regeneration when added exogenously in both long bone healing (Jackson *et al.* 2006) and cranial defect models (Blanquaert *et al.* 1995, Lafont *et al.* 2004). HS mimetics applied to a cranial defect model have shown an increase in new bone formation and neovascularization in the wound area over the first 5 days after injury. A single dose

application of HS to a rat femoral fracture at the time of injury has been demonstrated to increase callus size and bone volume after only 2 weeks (Jackson *et al.* 2006). Notably, these studies used single applications of HS in short-term delivery devices with promising results on the early stages of healing but triggered little difference in the later stages. Due to the temporal pattern of growth factor expression during bone repair, we have previously examined the prolonged localized delivery of HS over several days from polycaprolactone microcapsules (Luong-Van *et al.* 2007).

Fibrin glue enjoys widespread clinical application as a wound sealant, a reservoir to deliver growth factors and as an aid in the placement and securement of biological implants (Vasita *et al.* 2006, Inman *et al.* 2003, Pandit *et al.* 2000, DeBlois *et al.* 1994). Several studies have shown that fibrin glue promotes the regrowth of peripheral nerves to levels comparable with standard microsurgery, making it a popular candidate for experimental nerve repair (Shireman *et al.* 1998). In the cellular environment, fibrin specifically binds to a variety of proteins, including fibronectin, albumin, FGF2, VEGF, and IL-1 (Fakhry *et al.* 2005). These properties make it an interesting drug and cell delivery system for various applications in tissue engineering (Vasita *et al.* 2006, Inman *et al.* 2003, Pandit *et al.* 2000, DeBlois *et al.* 1994, Rai *et al.* 2005). Previous studies have focused on capabilities with respect to tailoring the scaffold to generate release profiles of the growth factors over time. Here, we investigated the bone regenerative capabilities of a single dose of HS encapsulated within a fibrin glue scaffold when implanted into a critical sized rat calvarial defect model. *In vitro*, we demonstrate the distribution and release of HS from fibrin glue scaffolds. *In vivo*, we utilized μ CT scanning, histological

examination and RQ-PCR of osteogenic markers to examine the effects of HS on the process of bone regeneration.

Materials and Methods

Scaffold Fabrication

Fibrin glue scaffolds were prepared using a commercial kit (TISSEEL kit; Baxter AG) as per the manufacturer's instructions. The mould for the cylindrical fibrin glue scaffold was a sterile, modified 1ml syringe (Figure 1A & B) that enabled easy application directly into the defect site once the scaffold had polymerized, so enhancing sterility by eliminating the need to handle any of the scaffolds (Figure 1C). Fibrinogen (25 μ l) was added to 25 μ l of thrombin solution, producing a polymerized scaffold of approximately 5 mm diameter and a thickness of 2 mm (Figure 1D). Two different concentrations of thrombin (Thrombin 4 and Thrombin 500) were investigated *in vitro* to optimize for the onset of *in vivo* experiments. The fibrin glue scaffolds created were used as a carrier-matrix for the heparan sulfate (HS) delivery as well as to fill up the bone defect site. To incorporate HS into the scaffold, 5 μ g (HS) was added to the thrombin component. This was thoroughly mixed and then pipetted into the sterile modified syringe body before adding the fibrinogen component. The ensuing polymerization of the glue and encapsulation of the HS took approximately 1 h. The scaffolds were then examined *in vitro* for a) HS release, to observe the release kinetics of HS from the fibrin glue; b) confocal microscopy, to observe the distribution of HS throughout the fibrin glue scaffold; and c) *in vivo* implantation and μ CT evaluation of bone mineralization and

histological examination. For the purpose of this study, all *in vitro* experiments were undertaken using Heparin (Sigma) as a control substitute for HS. Heparin is structurally similar to HS, and is believed to distribute and release in the same way within a scaffold. It can be easily conjugated to the fluorescent label Alexa Fluor-488, enabling its distribution to be localised and viewed using confocal microscopy, and its release quantified using fluorescent plate reading. All *in vivo* work utilized HS.

Confocal Microscopy

Heparin was fluorescently conjugated with Alexa Fluor-488 (A488, Molecular probes) using a method adapted from Osmond *et al.* (2002), prior to incorporation into the scaffold. To visualize the distribution of heparin, scaffolds were viewed using confocal laser scanning microscopy (Zeiss LSM S10 meta inverted microscope). Three dimensional depth projections were constructed from 100 horizontal slices of step size 10 μm .

Release Kinetics

Fibrin glue scaffolds containing 5 μg Alexa Fluor-488-labelled heparin were placed into 1 ml of pre-warmed phosphate buffered saline (PBS) and incubated at 37°C, protected from light, for a 7 day period. At each time point, 100 μl of PBS was removed for sampling and replaced with fresh PBS. The heparin released was quantified from the fluorescence intensity of the release media at 485 nm by comparison with a standard Alexa Fluor-488-heparin curve. The cumulative release was then graphed.

Surgery

The *in vivo* study involved the creation of two 5 mm diameter defects in the parietal bone. 20 female Wistar rats (300-400 gm) were used with approval from the Institutional Animal Care and Use Committee (IACUC), Singapore. They were randomly divided into 3 groups: (a) empty defects, (b) fibrin glue defects containing fibrin glue scaffold alone; and (c) fibrin glue defects containing fibrin glue scaffold encapsulated HS (5 µg).

Prior to surgery, the rats were given intra-peritoneal anesthesia of 75 mg/kg Ketamine & 1 mg/kg Medetomidine, the heads were shaved and saline-soaked gauze applied across the eyes. Under aseptic technique, the skin over the calvaria was disinfected with Betadine™, the skin over the parietal bone dissected in the sagittal plane and the periosteum removed from the both sides of the parietal bone. As previously described, a 5 mm diameter trephine was used to create two circular through-and-through, critical-sized bony defects¹ which were irrigated with saline to remove blood clots; hemostasis was achieved with gentle pressure. The fibrin glue scaffolds +/- HS were applied directly into the defect sites utilizing the novel syringe system. The skin was closed with 5-0 absorbable coated vicryl sutures (polyglactin 910, Johnson and Johnson). The animals were then given reverse anesthetics (5 mg/ml of antisedan), antibiotics and temegestic pain killers. They were placed individually in cages with food and water, and observed postoperatively for adverse effects.

Micro computed tomography (µCT) scanning

At 1 month and 3 months after surgery, the rats were anesthetized intra-peritoneally as previously described before undergoing μ CT scanning to obtain a quantitative measure of the levels of regenerated bone (SKYSCAN-1076 *in vivo* micro computerized tomography scanner, Belgium). As previously described, imaging was performed with 68 mm scan width, an Al-1 mm filter, 35 μ m pixel size, using an average of 4 sets of scan data per sample (Shao et al. 2006). All samples were scanned through a 180° rotation angle with a rotation step of 0.8° at 35 μ m resolution. The data were volumetrically reconstructed using cone beam CT reconstruction software from SKYSCAN at 1968x1968 pixels. Files were then reconstructed for analysis by Mimics v 8.11 software (Materialize, Belgium) using in-built functions. From the 3D image, a cylindrical region of interest (ROI) of defect size of 5 mm diameter was selected for analysis. This ROI corresponds to the original defect location. The degree of bone regeneration occurring within the defect was presented as a volume in mm³ of reconstructed data obtained in micro CT analysis. The threshold was adjusted empirically to visualize the defect site and the mineralization and was then kept constant for every sample (-284 to 1420 HUs for all reconstructions). Defect reconstruction was attained by subtracting the scanned mineralization data.

Histology and histomorphometry

Animals were sacrificed at 3 months in a CO₂ chamber. After euthanasia, tissue was dissected from the calvarial bone and the defect site sectioned for histology. For processing, tissue was fixed in 10% neutral buffered formalin for 2 days and de-calcified in 12.5% EDTA (Sigma Aldrich) pH 7.0 for 3 weeks. The samples were then serially dehydrated in ethanol in a tissue processor (Shandon Citadel 1000, Thermo Scientific),

and paraffin embedded (Leica EG 1160). Sections (5 μm) were taken using a microtome (Leica RM 2135). The slides were deparaffinized with xylene and rehydrated with serial concentrations of ethanol, before being stained with haematoxylin and eosin (Sigma Aldrich, USA) and mounted with DPX mountant (Fluka Biochemica, USA). Immunohistological staining was also used employing mouse monoclonal antibodies against type I collagen (Sigma Aldrich, USA) at 1:500 dilution, osteopontin (Santa Cruz) 1:50 dilution, and osteocalcin (Abcam, UK) at 1:150 dilution. Secondary antibodies were rat absorbed anti mouse IgG (Vector Labs, USA). The antigens were localized using an immunoperoxidase procedure according to the manufacturer's guidelines (VECTASTAIN[®] ABC kit, Vector Labs, USA). The isotype mouse IgG1 antibody was used as a negative control (Caltag Laboratories).

Histomorphometry was performed using Bioquant Osteo II software to quantify the percentage staining for collagen I, osteocalcin and osteopontin within the defect site. Briefly, a region of interest was manually drawn around the defect site. The entire defect site was first quantified (total area), and then the percentage of positive stain for each of the aforementioned proteins was quantified and expressed as a percentage of the entire defect site. This positive stain was obtained by manually thresholding the images and directing the software to pick up only the positive stains attributable to the protein of interest (attained through comparisons with negative controls). The thresholds were saved and applied to every slide within the data set, for each stain.

RNA isolation and RQ-PCR

Following sacrifice of the animals, the defect sites were surgically collected and immediately frozen using liquid nitrogen. The extracted tissue was then ground to powder form with a mortar and pestle. Total RNA was extracted using Trizol reagent (Invitrogen Corp., USA) and subsequent clean up using an RNeasy Mini Kit (QIAGEN, Singapore) according to the manufacturer's instructions. The quality of the isolated RNA was assessed by gel electrophoresis and quantitated on a Genequant RNA/DNA Spectrophotometer (Amersham Biosciences, Piscataway, NJ, USA) and stored at -80°C until further use. For conversion to cDNA, 500 ng of total RNA was reverse-transcribed using random hexamers catalysed by Superscript III RT (Invitrogen Corp., USA). Following spectrophometric quantitation of the cDNA, expression levels of the target genes were determined using RQ-PCR. Briefly, 120 ng of cDNA was amplified using the ABI Prism FAST 7500® sequence detection system (PerkinElmer Life Sciences, Wellesley, MA, USA) using the default cycle: 95°C x 20 sec followed by 40 cycles of 95°C x 3 sec, 60°C x 30 sec. Runx2, osteopontin and 18S primers and probes were designed using Primer Express software (v 2.1, PE Applied Biosystems, Foster City, CA, SA), and have been described elsewhere (Ng *et al.* 2007). Alkaline phosphatase primer and probes were purchased as an Assay-on-demand (PE Applied Biosystems, Foster City, CA, USA). The Runx2 and osteopontin LNA probes were re-designed to incorporate LNA bases and labeled with BHQ-1 (Proligo, Singapore). The ribosomal subunit gene 18S (VIC/TAMRA) was used as the endogenous control. Data was analyzed using the ABI Sequence Detector software. Amplifications were performed three times in triplicate. Target gene expression values were calculated relative to the endogenous control 18S expression levels using the (2^{-DDCt}) calculation.

Statistical analysis

A two-way ANOVA with differences considered significant at the 95% confidence interval, was used to determine significant differences between mineralization within the HS and non-HS treated scaffolds followed by the Bonferroni post-test. Standard error bars were included in all graphs and represent the 95% confidence interval.

Results

In vitro analysis of HS-loaded Fibrin glue scaffolds

To examine the distribution of heparin through the fibrin scaffold and to assess its time-release, a combination of confocal microscopy and fluorescent spectroscopy was performed. Confocal microscopy demonstrated a uniform distribution of heparin (HS substitute) throughout the fibrin scaffold. Sequential scans of 10 μm slices were taken and showed no significant change in heparin distribution between each slice throughout the whole body of the scaffold (data not shown). However, following several trials, the polymerization rate of Thrombin 500 was determined to be too rapid, prone to air bubbles and uneven encapsulation of the heparin component.

When we compared the release kinetics of heparin from the scaffold, using both Thrombin 4 and Thrombin 500 components, similarities were observed. The release from both scaffolds followed the same pattern; a fast initial burst with over 50% release within the first 4 h, followed by a sustained release over the course of 4 days, at which time

100% of the heparin had been released (Figure 2). As a result only the Thrombin 4 dosed scaffolds were used for the *in vitro* analyses.

In vivo analysis of HS-loaded fibrin glue scaffolds

The effect of HS on augmenting *in vivo* bone healing was first assessed by μ CT and histomorphometry. MicroCT scanning detected an increase in mineralization for those defect sites treated with HS at both 1 month and 3 months. Representative reconstructions of the defect sites at 1 month and 3 months for all treatments are presented in Figure 3. All treatments demonstrated significant increases from month 1 to 3 within their respective groups. At 3 months the HS-treated sites had full closure of the defect with mineralized bone. When quantiated using the MIMICs software, significantly higher mineralised bone was present in the HS treated sites at 3 months when compared with empty defect sites and fibrin glue alone defect sites ($p < 0.05$). No significant differences were observed between the treatment groups after 1 month.

We then examined the isolated and sectioned samples histologically using hematoxylin and eosin (H&E) staining and immunohistochemistry. The fibrin glue alone defect sites appear to have residual bone chips present from surgery, possibly owing to incomplete drilling through the parietal bone, and appear to be composed of newly formed bone with more intense and uniform staining, containing sparse non-contiguous islands within the defect area (Figure 4b). The empty defects appear to have only sparse fibrous connective tissue bridging between the bony fronts (Figure 4a). In the HS treated samples, newly formed, contiguous bone can be observed with and surrounding all edges of the defect site (Figure 4c). The osteogenic markers collagen type I, osteocalcin and osteopontin all

gave demonstrably higher staining within the HS treated groups when compared with empty defects. Collagen I was lowly detectable and disordered in both the empty and fibrin glue defect sites (Figures 4d and 4e). In contrast, in the HS-treated samples, collagen I had a more organized and fibrillar appearance along the direction of the fibrous tissue, contiguous with the structured bone edges of the defect site (Figure 4f). Osteocalcin staining was very low in both the empty and fibrin defect sites, with signal detected predominantly in the bone edges of the defect site (Figure 4g and 4h). In the HS-treated defect sites, osteocalcin staining was uniform throughout both the bone edges and the repaired defect site (Figure 4j). Osteopontin was very low in the empty defect samples (Figure 4j) but was present throughout the fibrin-treated defects (Figure 4k). The distribution of osteopontin throughout the HS-treated defects appeared to be mostly localised to the bone edges (Figure 4l). When we quantified the staining within the defect sites using Bioquant analyses, these observations were reinforced with HS-treated defects determined to have significantly higher levels of collagen type I, osteocalcin and osteopontin at 3 months (Figure 5).

RQ-PCR analysis of treatment sites

To further assess bone formation, we examined the osteogenic markers Runx2, alkaline phosphatase and osteopontin using RQ-PCR in the fibrin glue and HS treated samples. As expected, the fibrin glue alone samples demonstrated expression of all three osteogenic markers examined, confirming the presence of osteogenic-committed cells within the isolated defect sites. Significant upregulation of all markers was demonstrated in the HS-treated samples. Notably, Runx2 was upregulated 6-fold, alkaline phosphatase

3-fold and osteopontin 2-fold (data not shown). The comparison of the Runx2 and alkaline phosphatase data are presented in Figure 6.

Discussion

Bone is a dynamic and multifunctional organ capable of remodeling and self-regeneration. However, in extreme cases of non-union or delayed fracture union, therapeutic intervention is often required. In conventional procedures, the transplantation of bone requires invasive procedures including skin and mucosal incisions and resection of the periosteum. The ability to implant a bioactive scaffold with osteoinductive properties within a critical sized defect is an attractive one, especially if the therapy negates the requirement to include live cells in the scaffold.

It has been shown that the local or systemic application of a number of growth factors such as FGF2 and BMP2 (Fakhry *et al.* 2005, Blanquaert *et al.* 1995) can aid bone repair. Disadvantages of such applications include their rapid clearance rates and susceptibility to proteolytic degradation (Babensee *et al.* 2000). Additionally there is concern over their long-term safety and associated costs, particularly as large quantities are required. Heparan sulfate binds to a variety of soluble proteins involved in the control of cell phenotype, including heparin-binding growth factors. The HS mode of action is to concentrate growth factors close to cells, protect them from extracellular proteases, shepherd them to the cell surface and facilitate binding to their specific receptors (Zhang *et al.* 2002). The complexes formed can be readily dissociated and mobilized in the event

of tissue damage, resulting in prolonged bioactivity at the site of damage (Coombe *et al.* 2005). HS has been implicated in facilitating and stabilising the interaction of FGFs with their receptors. The more complicated interaction with BMPs have been demonstrated to include a stabilizing and storage role in the extracellular space (Ruppert *et al.* 1996), maintaining the growth factor spatially away from its receptor, thus limiting signaling potential (Takeda *et al.* 2003) and preventing diffusion from a site of injury (Depprich *et al.* 2005), however these interactions act in unison to modulate the activity and it has not yet been shown that HS interacts directly with the BMP2/receptor complex. Nonetheless, a synergistic interaction seems apparent between HS and BMP2, although the exact mechanism driving this is still unknown. We and others, have previously demonstrated increased bone regeneration through addition of HS and HS-like molecules. Heparan-like mimetics (carboxymethyl-bezylamide-sulfonated dextrans) have been reported to induce the repair of rat skull defects (Lafont *et al.* 2004), and single doses of HS have been shown to augment fracture repair in a rat model (Jackson *et al.* 2006).

Fibrin glue is a physiologically relevant matrix whose principle component, fibrin, has fundamental roles in the process of blood clotting and wound healing. It is also a potentially suitable biological vehicle for cell transplantation, as it has proven biocompatibility, biodegradability and binding capacity to cells (Mundlos *et al.* 1997). Fibrin stabilizing factor XIII, contained in fibrin glue, favours migration of undifferentiated mesenchymal cells on the highly cross linked structure of the glue and it enhances proliferation of these cells (Otto *et al.* 1997, Choi *et al.* 2005). The fibrin glue scaffolds in this study were comprised of a low concentration of thrombin (thrombin 4),

as the suitability and incorporation of the HS into the polymerizing glue proved difficult using higher concentrations (thrombin 500). Increasing the thrombin concentration has previously been demonstrated to affect fiber thickness, porosity and homogeneity of the fibrin (Pratap *et al.* 2003). Given the promising therapeutic potential of HS, this study sought to investigate the effects of HS on bone regeneration within a critical sized rat cranial defect using fibrin glue as a release reservoir.

Initial *in vitro* studies demonstrated heparin (the control for HS) was released rapidly in the first 4 h from the fibrin glue scaffolds, with over 50% of the total heparin released in the first 4 h, followed by a sustained release (up to 100% over 4 days). When applied *in vivo*, this sharp burst may provide a large, initial stimulus for growth factor recruitment and concentration and thus an accelerated onset of bone regeneration. Although the HS is not physically attached to the scaffold, and probably diffuses away from the wound site fairly rapidly, it appears that the initial high presence (~5ug) of HS within the site of injury is sufficient enough to stimulate an enhanced regenerative response. Indeed, the local gradient of HS within the vicinity of the wound site may provide an environment which produces a corresponding gradient of growth factors, a known stimulator for migrating cells. Such gradients may affect subsequent wound healing by guaranteeing a store of pre-activated growth factors immediately adjacent to the wound site, which in turn would act to stimulate the recruitment of more stem cells into the wound site.

We next examined how to determine the best doses and release profiles required for optimal bone regeneration over a longer period *in vivo*. We utilised μ CT scanning to determine bone mineralization within the defect sites and reinforced this with histological

and histomorphometrical examination of the defect sites and gene expression analyses of isolated tissue.

MicroCT analysis showed significant bone regeneration within defects treated with HS compared to empty defects and fibrin glue alone, with full closure of sites observed after 3 months. Histological analysis showed clear differences in tissue formation among the different treatment conditions. Sparse fibrous connective tissue was found to traverse the empty defects, compounded by the lowest levels of staining for collagen I, osteocalcin and osteopontin. In contrast, in the HS treated samples, newly formed bone was clearly observed surrounding all edges of the defect site, with contiguous bone within the defect site demonstrating intense and uniform staining for the osteogenic markers. Quantitative analysis reinforced the observed immunohistochemical data with significantly higher levels of collagen I, osteocalcin and osteopontin within the HS-treated defect sites. Additionally, using RQ-PCR, gene expression of key osteogenic markers was also demonstrated, with increased Runx2, alkaline phosphatase and osteopontin in the HS treated groups. It is of note that due to the amount of tissue available, the yield and quality of extracted RNA from the empty defect sites was significantly lower than the other treatment conditions. Runx2 is regarded as the key regulator of osteogenesis and has been shown to be essential for skeletal patterning during embryogenesis and the progression of osteoblast differentiation (Keller *et al.* 1985, Kasai *et al.* 1983, Marktl *et al.* 1974, Le Nihouannen *et al.* 2006, Ducy *et al.* 1999). Calvarial cells harvested from Runx2-deficient mice have increased rates of cell proliferation, DNA synthesis and G1/S phase markers; the reintroduction of Runx2 restores normal cell cycling, emphasizing the

importance of Runx2 for cell cycle regulation (Komori *et al.* 1997). Reports have suggested the addition of HS can increase the expression of Runx2, alkaline phosphatase and osteopontin in preosteoblast cells, suggesting the potential for exogenous HS to shift cells from proliferative to differentiative phenotypes (Jackson *et al* 2006). These results are consistent with this hypothesis.

The current study evaluated a previously verified dose of heparan sulfate encapsulated within a fibrin glue delivery system, for its ability to influence sustained bone repair within critical sized rat cranial defects. Our results suggest that by enhancing growth factor activity within the defect site, HS mediates increased bone repair reflected by increased mineralised bone and osteogenic marker expression. These data suggests the HS may have a significant therapeutic role in bone regeneration.

Acknowledgements

The Authors would like to thank Amber Annette Sawyer for training with Bioquant image analysis software.

Figure Legends:

Figure 1. Fibrin glue scaffold fabrication. Thrombin, fibrinogen and HS were mixed and polymerized in the barrel of a 1 ml modified syringe (A) and ejected after production (B). The sterile fibrin scaffold produced had dimensions of approximately 5 mm in diameter

and a thickness of 2 mm (D), which could then be easily implanted directly into the 5 mm defect sites (C).

Figure 2. In vitro analysis of release kinetics of Alexa-468-heparin from fibrin scaffolds revealed a sharp initial burst of over 50% total heparin released in the first 4 h followed by a sustained release of up to 100% over 4 days. ▲= Thrombin 500 ●=Thrombin 4.

Figure 3. Quantified μ CT analysis of defect sites at 1 month and 3 months for empty defect sites, fibrin glue alone and HS treated sites. Representative μ CT images were analysed using MIMICs evaluation of the total volume of mineralized bone, in mm^3 , detected within the defect sites. * denotes a significant difference between HS treated sites and all other defect sites at 3 months.

Figure 4. Representative photographs of tissue section analysis of haemotoxylin and eosin (a-c), and immunohistochemical staining for type I collagen (d-f), osteocalcin, g-i) and osteopontin (j-l) within each defect site after 3 months.

Figure 5. Quantitation of staining as a percentage of total tissue formation after 3 months determined using Bioquant image analysis software. * denotes a significant difference between HS treated sites and all other sites.

Figure 6. RQ-PCR analysis of osteogenic markers showing Runx2 and alkaline phosphatase expression comparing tissue from defect sites with fibrin glue alone and HS fibrin glue scaffolds at 3 months.

References

- Babensee JE, McIntyre LV, Mikos AG. (2000). Growth factor delivery for tissue engineering. *Pharm Res.* 17: 497-504.
- Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. (1995). Heparan-like molecules induce the repair of skull defects. *Bone.* 17: 499–506.
- Choi KY, Kim HJ, Lee MH, Kwon TG, Nah HD, Furuichi T, Komori T, Nam SH, Kim YJ, Kim HJ, Ryoo HM. (2005). Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. *Dev Dyn.* 233(1): 115–121.
- Cool SM, and Nurcombe V. (2005). The osteoblast-heparan sulfate axis: Control of the bone cell lineage. *The International Journal of Biochemistry & Cell Biology.* 37(9): 1739-1745.
- Coombe DR, Kett WC. (2005). Heparan sulfate-protein interactions: therapeutic potential through structure-function insights. *Cell Mol Life Sci.* 62: 410–24.
- Cowan CM, Shi YY, Aalami OO, Chou YF, Mari C, Thomas R, Quarto N, Contag CH, Wu B & Longaker MT. Adipose-derived adult stromal cells heal critical-size mouse calvarial defects; *Nature Biotechnology* 2004. 22: 560 – 567.
- DeBlois C, Cote MF, Doillon CJ. (1994). Heparin-fibroblast growth factor fibrin complex: in vitro and in vivo applications to collagen based materials. *Biomaterials.* 15(9): 665-672.
- Deprich R, Handschel J, Sebald W, Kubler NR, Wurzler KK (2005). [Comparison of the osteogenic activity of bone morphogenetic protein (BMP) mutants]. *Mund Kiefer Gesichtschir* 9: 363-368.
- Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G. (1999). A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. *Genes Dev.* 13(8): 1025–1036.
- Fakhry, A. (2005). Effects of FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. *Bone.* 36: 254–266.
- Guido D, Bernfield M. (1998). The emerging roles of cell surface heparan sulfate proteoglycans. *Matrix Biology.* 17(7): 461-463.
- Irie A, Habuchi H, Kimata K, Sanai Y. (2003). Heparan sulfate is required for bone morphogenetic protein-7 signaling. *Biochem Biophys Res Commun.* 308: 858–65.
- Jackson RA, Nurcombe V, Cool SM. (2006). Coordinated fibroblast growth factor and heparan sulfate regulation of Osteogenesis. *Gene.* 379: 79-91.
- Jackson RA, McDonald MM, Nurcombe V, Little DG, Cool SM. (2006). The use of heparan sulfate to augment fracture repair in a rat fracture model. *J Orthop Res* 24: 636–44.
- Kasai S, Kunimoto T, Nitta K. (1983). Cross linking of fibrin by activated factor XIII stimulates attachment, morphological changes and proliferation of fibroblasts. *Biomed Res.* 4: 155-160
- Keller J, Anderasses TT, Joyce F. (1985). Fixation of osteochondral fractures: fibrin sealant tested in dogs. *Acta Orthop Scand.* 56: 323-326.

- Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. (1997). Targeted disruption of *Cbfa1* results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell*. 89(5): 755–764.
- Lafont J, Blanquaert F, Colombier ML, Barritault D, Caruelle JP, Saffar JL. (2004). Kinetic study of early regenerative effects of RGTA11, a heparan sulfate mimetic, in rat craniotomy defects. *Calcif Tissue Int* 75: 517–25.
- Le Nihouannen D, Le Guehennens L, Rouillon T, Pilet P, Bilban M, Layrolle P, Daculsi G. (2006). Micro-architecture of calcium phosphate granules and fibrin glue composites for bone tissue engineering. *Biomaterials*. 27: 2716-2722.
- Luong-Van E, Grøndahl L, Nurcombe V, Cool SM. (2007). In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate. *Biomaterials*. 28: 2127–2136.
- Lyon M and Gallagher JT. (1998). Bio-specific sequences and domains in heparan sulfate and the regulation of cell growth and adhesion. *Matrix Biology*. 17(7): 485-493.
- Marktl W, Rudas B. (1974). The effect of factor XIII on wound granulation in the rat. *Thromb Diath Haemorrh*. 32: 578-581.
- Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR. (1997). Mutations involving the transcription factor *CBFA1* cause cleidocranial dysplasia. *Cell*. 89(5): 773–779.
- Ng KW, Spiecher T, Dombrowski C, Helledie T, Haupt LM, Nurcombe V and Cool SM. (2007). Osteogenic Differentiation of Murine Embryonic Stem Cells Is Mediated by Fibroblast Growth Factor Receptors. *Stem Cells and Development*. 16: 305–318.
- Ornitz DM, Marie PJ. (2002). FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. *Genes Dev*. 16: 1446–1465.
- Osmond RI, Kett WC, Skett SE, Coombe DR. (2002). Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization. *Anal Biochem*. 310: 199–207.
- Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. (1997). *Cbfa1*, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell*. 89(5): 765–771.
- Pandit AS, Wilson DJ, Feldman DS. (2000). Fibrin scaffold as an effective vehicle for the delivery of acidic growth factor (FGF-1). *J. Biomaterials Applications*. 14(3): 229-242.
- Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ. (2003). Cell growth regulatory Cell regulatory role of *Runx2* during proliferative expansion of preosteoblasts. *Cancer Res*. 63(17): 5357–5362.
- Rai B, Teoh SH, Hutmacher DW, Cao T, Ho KH. (2005). Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2. *Biomaterials*. 26: 3739-3748.
- Ruppert R, Hoffmann E, Sebald W (1996). Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. *Eur J Biochem* 237: 295-302.
- Saksela O and Rifkin D. (1989). Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity *Fibrinolysis*. 3: 36.

Shao XX, Hutmacher DW, Ho ST, Goh JC, Lee EH. (2006). Evaluation of a hybrid scaffold/cell construct in repair of high-load-bearing osteochondral defects in rabbits. *Biomaterials*. 27(7): 1071-80.

Shireman PK, Greisler HP. (1998). Fibrin Sealant in vascular surgery: a review. *Journal of Long term effects of Medical Implants*. 8: 117-132.

Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, Ogamo A, Kamijo R (2003). Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. *J Biol Chem* 278: 43229-43235.

Turnbull J, Powell A, Guimond S. (2001). Heparan sulfate: decoding a dynamic multifunctional cell regulator. *Trends in Cell Biology*. 11(2): 75-82

Vasita R, Katti DS. (2006). Growth factor delivery systems for tissue engineering: a materials perspective. *Expert Reviews in Medical Devices*. 3(1): 29-47.

Weisel JW. (2005). Fibrinogen and Fibrin. *Advanced Protein Chemistry*. 70: 247-299.

Wong C, Inman E, Spaethe R, Helgerson S. (2003). *Thromb.Haemost*. 89(3): 573-582.

Zhang X, Sobue T, Hurley MM. (2002). FGF-2 increases colony formation, PTH receptor, and IGF-1 mRNA in mouse marrow stromal cells. *Biochem. Biophys. Res. Commun*. 290: 526–531.
